{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Epidermolysis+Bullosa+Simplex",
    "query": {
      "condition": "Epidermolysis Bullosa Simplex"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 15,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Epidermolysis+Bullosa+Simplex&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T18:15:47.285Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03158662",
      "title": "Survey to Identify Burdens and Unmet Needs of Patients With Epidermolysis Bullosa",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Epidermolysis Bullosa"
      ],
      "interventions": [
        {
          "name": "Survey",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Amicus Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2017-04-02",
      "completion_date": "2017-06-30",
      "has_results": false,
      "last_update_posted_date": "2017-08-24",
      "last_synced_at": "2026-07-22T18:15:47.285Z",
      "location_count": 1,
      "location_summary": "Cranbury, New Jersey",
      "locations": [
        {
          "city": "Cranbury",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03158662"
    },
    {
      "nct_id": "NCT05062070",
      "title": "Safety and Efficacy of Topical TolaSure Targeting Aggregated Mutant Keratin in Severe Epidermolysis Bullosa Simplex",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Epidermolysis Bullosa Simplex"
      ],
      "interventions": [
        {
          "name": "TolaSure Topical Gel",
          "type": "DRUG"
        },
        {
          "name": "Vehicle Topical Gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioMendics, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2022-05-05",
      "completion_date": "2023-06-22",
      "has_results": false,
      "last_update_posted_date": "2023-09-11",
      "last_synced_at": "2026-07-22T18:15:47.285Z",
      "location_count": 1,
      "location_summary": "Redwood City, California",
      "locations": [
        {
          "city": "Redwood City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05062070"
    },
    {
      "nct_id": "NCT02090283",
      "title": "Open-Label Extension Study to Evaluate the Safety of SD-101 Cream in Participants With Epidermolysis Bullosa",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Epidermolysis Bullosa"
      ],
      "interventions": [
        {
          "name": "SD-101 dermal cream (6%)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Scioderm, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Months and older"
      },
      "enrollment_count": 42,
      "start_date": "2014-03-26",
      "completion_date": "2018-09-14",
      "has_results": true,
      "last_update_posted_date": "2019-11-04",
      "last_synced_at": "2026-07-22T18:15:47.285Z",
      "location_count": 7,
      "location_summary": "Palo Alto, California • Chicago, Illinois • St Louis, Missouri + 4 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02090283"
    },
    {
      "nct_id": "NCT03269474",
      "title": "Computational Drug Repurposing for All EBS Cases",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Epidermolysis Bullosa",
        "Healthy",
        "Genetic Skin Disease",
        "Epidermolysis Bullosa Simplex",
        "Epidermolysis Bullosa, Junctional",
        "Epidermolysis Bullosa Dystrophica"
      ],
      "interventions": [
        {
          "name": "Experimental Group",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Joyce Teng",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "0 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2017-11-28",
      "completion_date": "2024-12-31",
      "has_results": false,
      "last_update_posted_date": "2024-02-13",
      "last_synced_at": "2026-07-22T18:15:47.285Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03269474"
    },
    {
      "nct_id": "NCT07027345",
      "title": "A Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Epidermolysis Bullosa Simplex"
      ],
      "interventions": [
        {
          "name": "5% TolaSure Topical Gel",
          "type": "DRUG"
        },
        {
          "name": "Topical Placebo Gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioMendics, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "4 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2025-09",
      "completion_date": "2026-09",
      "has_results": false,
      "last_update_posted_date": "2025-09-11",
      "last_synced_at": "2026-07-22T18:15:47.285Z",
      "location_count": 2,
      "location_summary": "Palo Alto, California • Chicago, Illinois",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07027345"
    },
    {
      "nct_id": "NCT03154333",
      "title": "Safety and Efficacy of Diacerein 1% Ointment for Subjects With Epidermolysis Bullosa Simplex (EBS)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Epidermolysis Bullosa Simplex"
      ],
      "interventions": [
        {
          "name": "diacerein 1% ointment",
          "type": "DRUG"
        },
        {
          "name": "A placebo ointment",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Castle Creek Pharmaceuticals, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "4 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2017-06-01",
      "completion_date": "2018-10-31",
      "has_results": true,
      "last_update_posted_date": "2019-11-05",
      "last_synced_at": "2026-07-22T18:15:47.285Z",
      "location_count": 12,
      "location_summary": "Phoenix, Arizona • Palo Alto, California • Aurora, Colorado + 8 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03154333"
    },
    {
      "nct_id": "NCT03472287",
      "title": "To Evaluate the Pharmacokinetic of Diacerein and Rhein After Maximum Use in Patients With Epidermolysis Bullosa (EB)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Epidermolysis Bullosa (EB)",
        "Epidermolysis Bullosa Simplex",
        "Dystrophic Epidermolysis Bullosa",
        "Junctional Epidermolysis Bullosa"
      ],
      "interventions": [
        {
          "name": "Diacerein 1% Ointment",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Castle Creek Pharmaceuticals, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "4 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2018-05-18",
      "completion_date": "2019-02-14",
      "has_results": true,
      "last_update_posted_date": "2020-02-10",
      "last_synced_at": "2026-07-22T18:15:47.285Z",
      "location_count": 3,
      "location_summary": "Palo Alto, California • Chicago, Illinois • Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03472287"
    },
    {
      "nct_id": "NCT04213703",
      "title": "A Pilot Study to Explore the Role of Gut Flora in Epidermolysis Bullosa",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Epidermolysis Bullosa",
        "Epidermolysis Bullosa Simplex",
        "Epidermolysis Bullosa Dystrophica"
      ],
      "interventions": [
        {
          "name": "No intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "ProgenaBiome",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 0,
      "start_date": "2020-03-02",
      "completion_date": "2030-07",
      "has_results": false,
      "last_update_posted_date": "2025-06-05",
      "last_synced_at": "2026-07-22T18:15:47.285Z",
      "location_count": 1,
      "location_summary": "Ventura, California",
      "locations": [
        {
          "city": "Ventura",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04213703"
    },
    {
      "nct_id": "NCT02960997",
      "title": "Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Epidermolysis Bullosa Simplex",
        "Epidermolysis Bullosa Simplex Kobner",
        "Weber-Cockayne Syndrome"
      ],
      "interventions": [
        {
          "name": "Sirolimus, 2%",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "4 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2016-05",
      "completion_date": "2021-12-01",
      "has_results": true,
      "last_update_posted_date": "2022-03-09",
      "last_synced_at": "2026-07-22T18:15:47.285Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02960997"
    },
    {
      "nct_id": "NCT06073132",
      "title": "An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Generalized Epidermolysis Bullosa Simplex"
      ],
      "interventions": [
        {
          "name": "AC-203",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TWi Biotechnology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Months and older"
      },
      "enrollment_count": 80,
      "start_date": "2024-04-04",
      "completion_date": "2027-03",
      "has_results": false,
      "last_update_posted_date": "2026-07-09",
      "last_synced_at": "2026-07-22T18:15:47.285Z",
      "location_count": 7,
      "location_summary": "Rancho Santa Margarita, California • Stanford, California • Aurora, Colorado + 4 more",
      "locations": [
        {
          "city": "Rancho Santa Margarita",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06073132"
    }
  ]
}